Adial Pharmaceuticals, Inc. (ADIL) Stock Price & Analysis
Adial Pharmaceuticals, Inc. (ADIL) closed at USD 3.92 on Friday, October 23, 2026, down 7.11% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.92; the Oct 23, 2026 session ranged USD 3.92–4.28 on volume of 47,359 shares. Market capitalization is —, with a 52-week range of USD 1.31–9.5 (NCM). Source: Nexqual, retrieved October 24, 2026 at 11:50 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ADIL.md
Key facts (ADIL)
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $106K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -56.4% vs S&P 500 +13.4%; 5Y -99.8% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ADIL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$19.3M | -$10.9M | -$6.9M | -$8.3M | -$7.8M | -$57.7M |
| Net income | -$19.4M | -$12.7M | -$5.1M | -$13.2M | -$8.0M | -$57.8M |
| EPS (diluted) | -$650.00 | -$317.75 | -$90.00 | -$68.01 | -$11.93 | — |
| Free cash flow | -$12.0M | — | — | — | — | — |
| Cash + short-term investments | $6.1M | $4.0M | $2.8M | $3.8M | $5.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ADIL)
Insider purchases (SEC Form 4, open-market, last ~7 months) (ADIL)
3 purchases, $106K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-14…2026-07-16 | Coastlands Capital Lp | 3,233 | $9K | 2.69 | Too little history (no open-market trades in 2023–2025) | |
| 2026-07-09…2026-07-10 | Coastlands Capital Lp | 11,753 | $33K | 2.78 | Too little history (no open-market trades in 2023–2025) | |
| 2026-06-29 | Coastlands Capital Lp | 25,000 | $65K | 2.6 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ADIL)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Alliance Global Partners | Initiated | Buy | $11 |
Total return (dividends reinvested) (ADIL)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -56.4% | -99.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -56.6% | -71.3% |
| Volatility (annualized) | 101.2% | 122.1% |
| Max drawdown | -85.7% (Oct 2025→May 2026) | -99.9% (Nov 2021→May 2026) |
ADIL company outlook (results filed Aug 17, 2026)
- “The $38.5 million attributable to the Series A convertible preferred stock is expected to be reclassified as equity upon obtaining stockholder approval of its conversion to common stock.”
Quoted word-for-word from the SEC 8-K results press release.
ADIL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-2.58 | $-1.31 | +96.6% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-2.59 | $-0.80 | +223.7% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-1.05 | $-6.12 | -82.8% | $0 | 1 |
| Next fiscal year (ends Dec 2027) | $-7.45 | $-2.59 | +187.6% | $0 | 2 |
Key Statistics (as of October 24, 2026 at 11:50 UTC)
| Price | USD 3.92 |
|---|---|
| Change | ▼ 7.11% (down) |
| Previous Close | USD 3.92 |
| Open | USD 3.92 |
| Day Range | USD 3.92 – 4.28 |
| 52-Week Range | USD 1.31 – 9.5 |
| Volume | 47,359 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ADIL)
Nexqual's technical model rates ADIL "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 24, 2026 at 11:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.99 (neutral) |
| vs SMA50 | Below (USD 4.79) |
| MACD | -0.21 (negative) |
Earnings (ADIL)
| EPS Estimate | USD -2.58 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.29 vs est -0.91 ▼ miss |
| 2026-03-31 | USD -1.48 vs est -2.25 ▲ beat |
| 2025-12-31 | USD -11.48 vs est -2.13 ▼ miss |
| 2025-09-30 | USD -2 vs est -3.5 ▲ beat |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
Financials & Fundamentals (ADIL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -2011.64% |
| Current Ratio | 5.63 |
| Total Cash | $28.71M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
Ownership (ADIL)
| Insider Ownership | +7.08% |
|---|---|
| Institutional Ownership | +29.85% |
| Shares Outstanding | 2.63M |
| Float | 2.11M |
| Short % of Float | +7.01% |
Source: Nexqual, October 24, 2026 at 11:50 UTC.
From Adial Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Three patent and patent application families are included in the UVA LVG License, with patents issued in over 40 countries, including, without limitation, in the U.S., Europe and Eurasia.
- The license agreement, as amended on October 21, 2013, and further amended on May 18, 2016, March 27, 2017, August 15, 2017, December 14, 2017, December 18, 2018, December 31, 2019, and October 21, 2024 sets forth specific diligence milestones completion deadlines including using commercially reasonable efforts to submit an NDA with the FDA for a Licensed Product by March 31, 2028 and commence commercialization of an FDA approved Licensed Product by March 31, 2029.
- Ondansetron, the active pharmaceutical ingredient ("API") of AD04 was granted FDA approval as Zofran® for the treatment of post-operative and post-chemotherapy nausea and emesis in January 1991 and is now commercially available in generic form at doses from more than 12 times the AD04 dose to over 70 times the AD04 dose with the highest doses being administered intravenously ("i.v."), which provides almost twice the drug exposure levels as oral dosing.
- Our approach, if approved by FDA, may allow for social drinking to continue and is aimed at reducing the dangerous, heavy drinking.
Partnerships
- Our licensed therapeutic agent was the product candidate used in the ONWARD Phase 3 clinical trial of 302 patients as well as a University of Virginia investigator sponsored Phase 2b clinical trial of 283 patients. worldwide license agreement with UVA LVG for rights to make, use or sell licensed products in the United States based upon the patents and patent applications made and held by UVA LVG (the "UVA LVG License").
- As a result of our ongoing business and clinical development planning for AD04, we are approaching UVA LVG to extend the milestones referenced in our license agreement with UVA.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADTX | Aditxt, Inc. | USD 0 | ▼ 0% |
| NIKI | Niki BioSolutions, Inc. | USD 1.83 | ▼ 1.61% |
| BCDA | BioCardia, Inc. | USD 0.92 | ▼ 0.97% |
| PHIO | Phio Pharmaceuticals Corp. | USD 0.85 | ▼ 2.36% |
| BPTH | Bio-Path Holdings, Inc. | USD 0 | ▼ 0% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 11:50 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt